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LETTER TO THE EDITOR

Inaccurate conclusions by Tang and colleagues
I read with interest the study by Tang and colleagues, published

seeing in patients critically ill with COVID-19. Hospitals will need

March 27, 2020, entitled “Anticoagulant treatment is associated with

to establish safe ways to aggressively test for the presence of VTE

decreased mortality in severe coronavirus disease patients with co-

in these patients to inform therapeutic anticoagulation, focusing on

agulopathy.” Unfortunately, this retrospective study came to conclu-

minimizing exposure of health care workers to the virus.

sions that are inaccurate with the information provided.
The authors use of the word “therapy” implies that patients were
given therapeutic doses of anticoagulants; however, doses appear to
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be most consistent with prophylaxis dosing. The authors report that
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94 patients received enoxaparin at 40 to 60 mg/day. They did not
specify the route of administration, subcutaneous or intravenous,
nor did they specify the percentage of patients that received which
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dose. The 40 mg/day dose of enoxaparin given subcutaneous is the

and Rheumatology, Department of Medicine, Rutgers – New

prophylactic dose. The 60 mg/day intravenous dose would be ther-
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apeutic for patients weighing 40 kg, which is not a typical weight for
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an adult patient.
Review of the aforementioned suggests that the authors are re-
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ally presenting data demonstrating that hospitalized COVID-19 pa-
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tients should be on venous thromboembolism (VTE) prophylaxis, a
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position that should be unanimously supported as standard of care
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based on prior research that suggests that 11% of patients would de-
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velop VTE.1 This has recently been reaffirmed by The International
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Society of Thrombosis and Haemostasis in their March 25, 2020,
guidelines. 2
There is concern that patients with COVID-19 are at higher risk of
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developing VTE. I am aware of just one study to date that attempted
to elucidate the prevalence of VTE.3 This retrospective study reported
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(DVT). It is important to note that none of the 81 patients received
VTE chemical prophylaxis and the authors of that study did not mention whether patients received mechanical prophylaxis either. At my
institution, we have diagnosed several critically ill COVID-19 patients
with acute lower extremity DVTs with point-of-care ultrasonography.
These patients developed DVTs despite chemical VTE prophylaxis.
The American Society of Hematology recommends against empiric therapeutic anticoagulation for COVID-19 patients given lack
of evidence of benefit and potential harm.4 As the world fights this
pandemic, high-quality prospective studies are required to further
elucidate the best way to manage the coagulopathy that we are
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